26 July 2021 - GlaxoSmithKline today announced that the US FDA has approved Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or who will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy.

This approval for a new population was based on clinical studies examining the safety and efficacy of Shingrix in adults (=18 years of age) who had undergone an autologous haematopoietic stem cell transplant and those undergoing treatment for hematological malignancies (post hoc analysis).

Read GSK press release